June 8, 2022 – Medical radioisotopes NorthStarLLC (NorthStar), a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Curie Therapy Inc., a therapeutic company dedicated to transforming cancer care with precision radiopharmaceuticals, has announced the signing of a long-term priority access agreement for the supply of the therapeutic medical radioisotope actinium-225 (Ac-225).

Under the terms of the agreement, NorthStar will give Curie Therapeutics priority access to its manufactured electron accelerator, the nca Ac-225. Ac-225 is a high-energy alpha-emitting radioisotope that, when combined with a targeting ligand, is of growing interest in the treatment of solid tumors. Ac-225 carries enough radiation to cause cell death in a localized area of ​​target cells. NorthStar will use its electron acceleration technology to produce the nca Ac-225, which does not contain long-lived radioactive contaminants and by-products from other manufacturing methods that pose regulatory and waste management challenges for hospitals and healthcare systems.

“NorthStar defines the supply chain for commercially, reliably and environmentally preferred production of therapeutic radioisotope products. We are excited to partner with Curie Therapeutics, a emerging leader in precision radiopharmaceutical development, ”said Stephen Merrick, President and CEO of NorthStar Medical Radioisotope. “Clinical trials and commercial use of the Ac-225 are severely limited by chronic shortages due to limitations in current manufacturing technologies. Our company is positioned to be the first commercial-scale manufacturer of the Ac-225, using our production technology nca Ac-225, which uses the latest production of electron beam accelerators, which provides increased capacity and flexibility in planning. Construction of our special production facility for Actinium-225 has begun, with initial production of the radiochemical class Ac-225 scheduled for the end of 2023. We expect to present a major FDA drug file in 2024, which will allow NorthStar upon adoption. to provide cGMP class Ac-225. We are very pleased to enter into this Ac-225 supply agreement with Curie Therapeutics and look forward to a productive relationship as we both strive to ensure the availability of targeted radiopharmaceutical therapy for cancer patients.

“Curie Therapeutics is extensively developing precision-targeted radiopharmaceuticals to meet the high unmet needs of treating solid tumors,” said Simon Reed, Ph.D., CEO. “Curie Therapeutics ligands are designed to achieve deep, homogeneous tumor distribution combined with rapid clearance. NorthStar is widely recognized for its leadership in cutting-edge radioisotope technology. This agreement guarantees our internal sources of Ac-225, now and in the future, which allows us to pursue our mission to provide innovative, safe and effective treatment for patients with solid tumor cancer.

For more information: www.northstarnm.com

Related content:

NorthStar Medical Radioisotopes and Convergent Therapeutics announce agreement to supply therapeutic radioisotope actinium-225 (Ac-225)

HFR Reactor Interruption Update – Medical Isotope Delivery Returns to Normal

Update for unplanned HFR reactor outages

SNMMI has issued a warning that disruption of HFR will affect isotope delivery

NorthStar Medical Radioisotopes is advancing its focus on therapeutic and specialized SPECT radiopharmaceutical products

How nuclear fusion revolutionizes the production of medical isotopes

FDA Approves Additional Molybdenum-99 (Mo-99) Charging Lines at NorthStar Medical Radioisotopes

The medical isotope industry opposes the export of highly enriched uranium to the IRE

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Allow Global Availability of Tc-99m


Previous articleStart your open source journey with Community Exchange
Next articleThe reorganization of HoloLens; Is Horizon’s plan to back up Crayta Meta? – Information